Chronic B-Cell Leukemia (CBCL) Overview

Save information for later
Sign Up

Learn About Chronic B-Cell Leukemia (CBCL)

View Main Condition: Leukemia

What is the definition of Chronic B-Cell Leukemia (CBCL)?
Chronic B cell leukemia is a type of chronic lymphocytic leukemia (CLL), or cancer of the blood and bone marrow that mainly affects adults. In chronic B cell leukemia, the bone marrow produces too many B lymphocytes, which are white blood cells that fight infection. Chronic B cell leukemia represents 95% of all chronic lymphocytic leukemias.
What are the symptoms of Chronic B-Cell Leukemia (CBCL)?
Individuals with early chronic B cell leukemia may not have any symptoms. Symptoms of intermediate and advanced stage chronic B cell leukemia may include painless, enlarged lymph nodes; fatigue; fever; pain in the upper left region of the abdomen; enlarged spleen; easy bruising or bleeding; pinpoint, dark red spots under the skin (petechiae); night sweats; weight loss; and frequent infections.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chronic B-Cell Leukemia (CBCL)?
Treatment for chronic B cell leukemia depends on the stage. Early stage chronic B cell leukemia may not need treatment and may involve watchful waiting. Treatment for intermediate and advanced stages chronic B cell leukemia may include targeted therapy, chemotherapy, radiation therapy, immunotherapy, and bone marrow or peripheral stem cell transplant.
Who are the top Chronic B-Cell Leukemia (CBCL) Local Doctors?
Danielle M. Brander
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Danielle M. Brander
Hematology Oncology | Hematology | Oncology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Danielle M. Brander
Hematology Oncology | Hematology | Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Danielle Brander is a Hematologist Oncology specialist and a Hematologist in Durham, North Carolina. Dr. Brander is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration. Dr. Brander is currently accepting new patients.

Steven T. Rosen
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Steven T. Rosen
Hematology Oncology | Hematology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Steven T. Rosen
Hematology Oncology | Hematology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
626-396-2900
Languages Spoken:
English
See accepted insurances

Steven Rosen is a Hematologist Oncology specialist and a Hematologist in South Pasadena, California. Dr. Rosen is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Thomas J. Kipps
Hematology Oncology | Oncology | Hematology
Elite in Chronic B-Cell Leukemia (CBCL)
Dr. Thomas J. Kipps
Hematology Oncology | Oncology | Hematology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Kipps is a Hematologist Oncology specialist and an Oncologist in San Diego, California. Dr. Kipps is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Leukemia.

View All Doctors
What are the latest Chronic B-Cell Leukemia (CBCL) Clinical Trials?
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
Who is this study for: Children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ...

View All Clinical Trials